Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | FADS1 | O60427 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22629682 | 0.85 | CA2 (0.69) | MEN1KMT2ACA2MTORFADS1 | |
| SCHEMBL14445018 | 0.85 | MEN1 (0.63) | MEN1KMT2ACA2MTORFADS1 | |
| SCHEMBL14986226 | 0.84 | CA2 (0.58) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL14983609 | 0.82 | MEN1 (0.52) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL2625550 | 0.81 | KMT2A (0.62) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL11224931 | 0.81 | CA12 (0.61) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL104492 | 0.81 | ALDH1A1 (0.59) | MEN1KMT2ACA2FADS1HSD17B10 | |
| SCHEMBL2096086 | 0.81 | FADS1 (0.59) | MEN1KMT2ACA2MTORFADS1 | |
| SCHEMBL2096083 | 0.81 | FADS1 (0.59) | MEN1KMT2ACA2CA1CA9 | |
| SCHEMBL22328192 | 0.81 | MEN1 (0.58) | MEN1KMT2ACA2MTORFADS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20210309665-A1 | COMPOUND HAVING TRKA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR ALLEVIATING PAIN, CONTAINING SAME AS ACTIVE INGREDIENT | JBKLAB CO., LTD (KR) | 2021-10-07 | — | — | US | disclosed |
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200054614-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | MEN1 1926/4885KMT2A 3925/4885CA2 3249/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | MEN1 1172/4885KMT2A 4131/4885CA2 2962/4885 |
| US-20210309665-A1 | COMPOUND HAVING TRKA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR ALLEVIATING PAIN, CONTAINING SAME AS ACTIVE INGREDIENT | NGF, OPRL1, TRPV1 | MEN1 3901/4885KMT2A 2738/4885CA2 1569/4885 |
| US-20200054614-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | MEN1 1612/4885KMT2A 4024/4885CA2 4606/4885 |
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | MEN1 1612/4885KMT2A 4024/4885CA2 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.